Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1 1

Status

Completed 6Active not recruiting 3Terminated 2Unknown 1Recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Head & Neck 1Gynecologic 1

Conditions

Colorectal Neoplasms 30Carcinoma, Hepatocellular 17Ovarian Neoplasms 14Fallopian Tube Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasms 8Glioblastoma 7Liver Neoplasms 6Lung Neoplasms 5Colonic Neoplasms 5Breast Neoplasms 5Neoplasm Metastasis 4Carcinoma, Renal Cell 4Brain Neoplasms 4Stomach Neoplasms 3Rectal Neoplasms 3Melanoma 3Carcinoma, Ovarian Epithelial 3Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Nasopharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoid Interstitial Pneumonia 2Colorectal Cancer Metastatic 2Brenner Tumor 2Advanced Solid Tumors 2Adenocarcinoma, Mucinous 2Virus Diseases 1

Interventions

Cisplatin 10pembrolizumab 8Carboplatin 8Paclitaxel 6durvalumab 5Pemetrexed 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5osimertinib 4Specimen Handling 4Magnetic Resonance Spectroscopy 4Taxes 3Nivolumab 3Gemcitabine 3Docetaxel 3Bevacizumab 3cabozantinib 2atezolizumab 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Platinum 2Immunoglobulin G 2Disulfides 2CP protocol 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2trifluridine tipiracil drug combination 1tremelimumab 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma × Bevacizumab × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT01061515 2025-09-17

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

Washington University School of Medicine

Phase 1 Active not recruiting
21 enrolled
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡